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Abstract 
Background: Biomarkers of inflammation and adiponectin are associated with cardiovascular autonomic neuropa-
thy (CAN) in cross-sectional studies, but prospective data are scarce. This study aimed to assess the associations of 
biomarkers of subclinical inflammation and adiponectin with subsequent changes in heart rate (HR) and heart rate 
variability (HRV) in non-diabetic and diabetic individuals.
Methods: Data are based on up to 25,050 person-examinations for 8469 study participants of the Whitehall II cohort 
study. Measures of CAN included HR and several HRV indices. Associations between baseline serum levels of high-
sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, IL-1 receptor antagonist (IL-1Ra) and adiponectin and 5-year 
changes in HR and six HRV indices were estimated using mixed-effects models adjusting for age, sex, ethnicity, body 
mass index (BMI), metabolic covariates and medication. A modifying effect of diabetes was tested.
Results: Higher levels of IL-1Ra were associated with higher increases in HR. Additional associations with measures 
of HRV were observed for hsCRP, IL-6 and IL-1Ra, but these associations were explained by BMI and other confound-
ers. Associations between adiponectin, HR and HRV differed depending on diabetes status. Higher adiponectin levels 
were associated with more pronounced decreases in HR and increases in three measures of HRV reflecting both 
sympathetic and vagal activity, but these findings were limited to individuals with type 2 diabetes.
Conclusions: Higher IL-1Ra levels appeared as novel risk marker for increases in HR. Higher adiponectin levels were 
associated with a more favourable development of cardiovascular autonomic function in individuals with type 2 
diabetes independently of multiple confounders.
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Background
Cardiovascular autonomic neuropathy (CAN) is a fre-
quent complication in patients with type 2 diabetes with 
prevalences reaching up to 60% after a disease duration 
of 15 years [1]. CAN is also observed in individuals with 
prediabetes and in older people, although in less severe 
forms [2] In addition to established cardiometabolic risk 
factors, CAN is an independent predictor of cardiovas-
cular morbidity such as myocardial ischaemia and stroke, 
progression of diabetic nephropathy and overall mortal-
ity [3–5].
Symptoms of CAN are usually preceded by pathologi-
cal changes in indices of resting heart rate (HR) and its 
variability (HRV) occurring early after the manifestation 
of diabetes, but also in early non-diabetic dysglyceamia 
[6]. Measurements of HRV are commonly used for the 
objective assessment of cardiac autonomic function in 
epidemiological studies and for the analysis of its associa-
tion with novel risk factors in the early stages of CAN [7].
Open Access
Cardiovascular Diabetology
*Correspondence:  christian.stevns.hansen@regionh.dk 
1 Steno Diabetes Center Copenhagen, Niels Steensens Vej 2-4, 
2820 Gentofte, Denmark
Full list of author information is available at the end of the article
Page 2 of 9Hansen et al. Cardiovasc Diabetol  (2017) 16:153 
Risk factors for CAN are only partly understood. Old 
age, hyperglycaemia and further obesity-associated met-
abolic derangements contribute to the incidence of CAN, 
so that optimised glycaemic control and a multifactorial 
approach targeting cardiovascular risk factors using life-
style-based and pharmacological strategies represent the 
cornerstone of current prevention guidelines [1] How-
ever, there are currently no therapeutic options aiming at 
other pathomechanisms of CAN. One of the mechanisms 
that has been implicated in the development of CAN is 
subclinical inflammation [7, 8]. Higher levels of proin-
flammatory biomarkers of inflammation such as high-
sensitivity C-reactive protein (hsCRP) and interleukin 
(IL)-6 have been found associated with impaired HRV 
and higher odds of CAN [7]. Additionally, higher rather 
than lower circulating levels of the insulin-sensitising 
and potentially atheroprotective adipokine adiponectin 
[9] have been shown to be associated with CAN [10] or 
reduced HRV [11] in patients with type 2 diabetes.
Importantly, almost all available data on the relation-
ship between subclinical inflammation and HRV or CAN 
are based on cross-sectional studies which does not allow 
for conclusions on causality, as the direction of associa-
tions may be bidirectional (reverse causality). Given the 
bidirectional interaction between the autonomic nervous 
system and inflammation [8] and the risk of reverse cau-
sality in the association between inflammation and cardi-
ovascular phenotypes [12], large prospective studies are 
needed to elucidate the temporal relationships between 
biomarkers of inflammation including adiponectin and 
CAN.
Therefore, we aimed to investigate the prospective 
associations of baseline levels of biomarkers of subclini-
cal inflammation [hsCRP, IL-6, IL-1 receptor antago-
nist (IL-1Ra)] and adiponectin with subsequent 5-year 
changes in HR and HRV in individuals with and without 
diabetes in large cohort.
Methods
Study participants, procedures and measurements
Participants are from the Whitehall II Study, an occupa-
tional cohort of 10,308 British civil servants (6896 men 
and 3412 women aged 35–55 years) of mainly white eth-
nicity recruited between 1985 and 1988 (phase 1) [13].
The cohort has been followed at eight subsequent 
phases. Every second phase (~  5  years apart) included a 
clinical health examination (phases 1, 3, 5, 7, and 9). Data 
from phases 3, 5, 7, and 9 form the basis for this study as 
measurements of inflammation, HR, HRV and a standard 
2-h 75  g OGTT were performed at those phases. Diabe-
tes was diagnosed at screening by OGTT (WHO criteria) 
or by self-reported diagnosis. Participants fasting  ≥  8  h 
were classified as having diabetes if fasting- or 2-h plasma 
glucose value were ≥ 7.0 or 11.1 mmol/l respectively. Par-
ticipants fasting < 8 h were classified with diabetes if any 
of their two glucose measurements were  ≥  11.1  mmol/l. 
Blood pressure and lipids were measured as described [13]. 
Patients with heart disease including ischemic heart disease 
and arrhythmias at baseline were excluded from analyses.
During follow-up, participants were censored if they 
died, were lost to follow-up or developed heart disease 
e.g. ischemic heart disease and arrhythmias either diag-
nosed at study examination or by register based follow-
up, which comprised 1809 (6.0%) person-examinations.
Serum levels of hsCRP, IL-6, IL-1Ra and total adiponec-
tin were measured as described [14, 15]. We excluded 
543 (1.9%) person-examinations with hsCRP > 10 mg/l as 
indicator of acute infections.
Five-minute resting 12-lead ECG recordings were 
obtained subsequent to 5 min of supine rest. Recordings 
were filtered through an automated algorithm, allowing 
the analyses of suitable R–R intervals without the pres-
ence of arrhythmias, ectopic beats and branch blocks. 
Indices of HRV were analysed in the time domain [the 
standard deviation of all intervals between R waves with 
normal-to-normal conduction (SDNN) and the root 
mean square of the sum of the squares of differences 
between consecutive R–R intervals (RMSSD)] and by 
utilizing a Blackman-Tukey algorithm also in the fre-
quency domain low-frequency (LF) power (in the 0.04–
0.15  Hz frequency band), high-frequency (HF) power 
(in the 0.15–0.4 Hz frequency band) and total power (in 
the ≤ 0.4 Hz frequency band). The ratio between LF and 
HF power (LF/HF ratio) was calculated.
Information on smoking habits, physical activity and 
medication use were gathered by self-administered ques-
tionnaires [13].
Statistical analysis
This analysis used HR and six HRV indices (SDNN, 
RMSSD, HF power, LF power, LF/HF ratio and total 
power) as outcomes. All except HR were log-transformed 
prior to analysis to fulfil the assumption of normally dis-
tributed model residuals.
The following biomarkers of subclinical inflammation 
were included as exposures: hsCRP, IL-6, IL-1Ra and adi-
ponectin (all  log2 transformed). Adiponectin and IL-1Ra 
were measured only in a case-cohort subsample nested 
within the Whitehall II study. [14, 15].
Up to 25,050 person-examinations for 8469 partici-
pants were analysed (9459 person-examinations for the 
3421 participants in the subcohort). In each 5-year obser-
vation window of two consecutive phases, we studied the 
associations of baseline levels of biomarkers of subclini-
cal inflammation and follow-up levels of the different 
outcomes, adjusting for baseline level of the outcome.
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All analyses were adjusted for age, sex, ethnicity, study 
phase and diabetes (model 1). Additional adjustments 
included BMI and physical activity (model 2) and smok-
ing, systolic blood pressure, total cholesterol, triglycer-
ides, tricyclic antidepressants, diuretics and beta blockers 
(model 3). For all outcomes except HR, analyses were also 
adjusted for HR obtained as part of the HRV analyses. To 
compare the estimated associations across models 1–3 
for a given outcome and exposure, we used a complete-
case approach, limiting the analyses to data with com-
plete information on all covariates in model 3. The same 
individual may contribute with more than one observa-
tion to the analyses. To account for the likely correlation 
of repeated measurements within the same participant, 
we used mixed-effects models with a random intercept 
and a random slope for time. Individuals changing diabe-
tes state during the study contributed with person-exam-
inations first to the non-diabetes group and later to the 
diabetes group.
Since prospective studies on adiponectin and cardio-
vascular outcomes have indicated that the direction of 
the association may depend on diabetes status (positive 
associations between adiponectin and cardiovascular 
events or mortality in individuals with diabetes rather 
than inverse associations in non-diabetic individuals) 
[16], we tested for a modifying effect of diabetes on the 
association between HR and HRV indices with adiponec-
tin. As sensitivity analysis, we also calculated models 
including interaction terms with diabetes for the three 
biomarkers of inflammation (i.e. hsCRP, IL-6 and IL-
1Ra). To assess if body composition estimated by waist 
circumference instead of BMI would affect model esti-
mates, we repeated the analyses replacing BMI with waist 
circumference.
Heart rate and HRV indices are highly interrelated, and 
the same is true for the inflammation-related biomarkers 
and adiponectin. Therefore, correction for multiple test-
ing would likely inflate the risk of type II errors and was 
therefore not applied.
Statistical analyses were performed in R version 3.3.1 
(The R Foundation for Statistical Computing) and SAS 
version 9.2 (SAS Institute, Cary, NC).
Results
The study population included 7769 participants at the 
first study phase and 5427 individuals at the last study 
phase. Median time between two subsequent phases was 
5.4 years (25th; 75th percentiles 5.0; 5.8 years). The prev-
alence of diabetes increased from 3.0 to 12.8%. Serum 
levels of hsCRP and IL-6 increased during follow-up, 
while levels of IL-1Ra and adiponectin remained sta-
ble. All indices of HRV decreased over the study period 
(Table 1).
For hsCRP, IL-6 and IL-1Ra, we found no modifying 
effect of diabetes on any of the associations, therefore 
results are presented for the whole study sample com-
bined, adjusting for diabetes (Table  2). Higher baseline 
levels of IL-1Ra were associated with larger increases in 
HR at all adjustment levels. Conversely, higher IL-1Ra 
was associated with a decrease in SDNN, LF power and 
total power in model 1, but effects were attenuated after 
further adjustment for BMI and physical activity. Higher 
levels of hsCRP were associated with more pronounced 
increases in HR, and both hsCRP and IL-6 were associ-
ated with larger decreases in the LF/HF ratio, but again 
these associations were partially mediated by BMI and 
not significant in subsequent models (Additional file  1: 
Table S1).
In contrast, we found a modifying effect of diabetes on 
the association between serum levels of total adiponec-
tin and future changes in HR and several HRV indices. 
In participants with type 2 diabetes, higher levels of total 
adiponectin were associated with a decrease in HR and 
increases in values of SDNN and RMSSD (time-domain 
indices) and of the LF power (frequency-domain index) 
(Table  3). These association were not only significant 
after initial adjustment for age, sex, ethnicity, diabetes, 
HR and study phase, but remained largely unaffected 
by further adjustment for BMI, lifestyle factors, blood 
pressure, serum lipids and medication (tricyclic antide-
pressants, diuretics and beta blockers). In contrast, non-
diabetic individuals only showed an inverse association 
between adiponectin and HR in model 1 (Table 3).
Adjusting for waist circumference instead of BMI did 
not affect model estimates (Additional file 1: Table S1 and 
Additional file 2: Table S2).
Discussion
This study has two major findings: (i) Higher baseline 
levels of hsCRP, IL-6 and IL-1Ra showed associations 
with larger increases in HR and decreases in several HRV 
indices after initial adjustment for age, sex and diabetes 
status. BMI represented a substantial confounder for all 
associations expect for the one between higher IL-1Ra 
levels and larger increases in HR, which remained signifi-
cant in the fully adjusted model. (ii) Higher baseline adi-
ponectin levels were association with smaller increases in 
HR and larger increases in HRV indices reflecting both 
sympathetic and vagal activity. However, these associa-
tions were present only in individuals with type 2 diabe-
tes, but absent in the non-diabetic study population.
Biomarkers of subclinical inflammation (hsCRP, IL‑6, 
IL‑1Ra), HR and HRV
Our data on biomarkers of subclinical inflammation, HR 
and HRV are novel, as only two small prospective studies 
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that investigated the temporal relationship between 
hsCRP and vagal tone assessed by HRV measurement of 
HF power [17, 18].
We show that higher IL-1Ra levels were associated with 
more pronounced increases in resting HR after adjust-
ment for a range of potentially confounding factors. 
Given the established link between higher resting HR 
and increased risk of cardiovascular outcomes (e.g. cor-
onary heart disease, sudden cardiac death, stroke, atrial 
fibrillation) and mortality [19], this finding implicates 
cytokines of the IL-1 family in the regulation of HR and 
in cardiovascular risk. As antagonist of the proinflam-
matory cytokine IL-1β, IL-1Ra has no agonist activity of 
its own and is thus unlikely to impair cardiac function 
[20]. Higher IL-1Ra levels are related to a higher risk of 
cardiovascular events in population-based studies [21] 
and have been proposed to reflect the presence of meta-
bolic and/or inflammation-related cardiovascular risk 
Table 1 Characteristics of the study population at each study phase
Data are means (SD), medians (25th; 75th percentiles) or proportions (95% CI)
a At phase 3, we are not able to separate tricyclic antidepressants from other antidepressants
b Subsample (n = 9459 records)
Phase 3 (1991–1993) Phase 5 (1997–1999) Phase 7 (2002–2004) Phase 9 (2007–2009)
N 7769 6105 5749 5427
Men (%) 69.4 (68.3; 70.4) 70.9 (69.8; 72.1) 70.5 (69.3; 71.6) 70.0 (68.8; 71.2)
White ethnicity (%) 90.3 (89.6; 91.0) 91.8 (91.1; 92.5) 92.1 (91.3; 92.8) 91.9 (91.2; 92.6)
Age (years) 50.0 (6.0) 55.6 (6.0) 60.8 (5.9) 65.5 (5.8)
Height (cm) 171.9 (9.5) 172.1 (9.2) 171.0 (9.3) 170.7 (9.3)
BMI (kg/m2) 25.3 (3.7) 26.1 (3.9) 26.5 (4.2) 26.7 (4.4)
Waist circumference (cm) 85.7 (11.5) 90.5 (11.7) 93.1 (12.1) 94.5 (12.0)
Current smokers (%) 13.0 (12.3; 13.8) 9.5 (8.8; 10.3) 7.9 (7.2; 8.6) 5.5 (4.9; 6.1)
Moderate to vigorous exercise (hours/week) 2.0 (1.0; 5.0) 11.8 (4.8; 20.3) 11.5 (4.3; 20.0) –
Alcohol intake (units/week) 6.0 (2.0; 14.0) 9.0 (3.0; 20.0) 8.0 (3.0; 17.0) 7.0 (2.0; 15.0)
Diabetes (%) 3.0 (2.6; 3.4) 5.6 (5.1; 6.2) 8.9 (8.1; 9.6) 12.8 (11.9; 13.7)
Medication
 Antihypertensive treatment (%) 6.7 (6.2; 7.3) 11.5 (10.7; 12.3) 21.2 (20.1; 22.3) 32.7 (31.4; 34.0)
 Lipid-lowering treatment (%) 0.7 (0.5; 0.9) 2.5 (2.1; 2.9) 9.2 (8.5; 10.0) 29.9 (28.7; 31.1)
 Tricyclic antidepressants (%)a 1.9 (1.6; 2.2) 2.7 (2.3; 3.1) 2.9 (2.5; 3.4) 3.5 (3.0; 4.0)
 Diuretics (%) 6.1 (5.6; 6.7) 3.0 (2.6; 3.5) 7.6 (7.0; 8.4) 10.8 (10.0; 11.7)
 Beta blockers (%) 0.6 (0.4; 0.8) 4.7 (4.2; 5.3) 8.0 (7.3; 8.7) 7.4 (6.7; 8.1)
Blood measurements
 Total cholesterol (mmol/l) 6.5 (1.2) 5.9 (1.1) 5.8 (1.0) 5.3 (1.1)
 HDL cholesterol (mmol(l) 1.4 (0.4) 1.5 (0.4) 1.6 (0.4) 1.6 (0.5)
 LDL cholesterol (mmol/l) 4.4 (1.0) 3.9 (0.9) 3.6 (0.9) 3.1 (1.0)
 Triglycerides (mmol/l) 1.5 (1.1) 1.4 (0.9) 1.4 (0.9) 1.3 (0.7)
 Systolic blood pressure (mmHg) 120.6 (13.6) 123.0 (16.5) 128 (16.8) 125.7 (16.1)
 Diastolic blood pressure (mmHg) 79.7 (9.4) 77.5 (10.6) 74.4 (10.4) 71.3 (10.2)
 CRP (mg/dl) 0.9 (0.4; 1.8) 1.0 (0.5; 2.0) 1.2 (0.6; 2.4) –
 IL-6 (pg/ml) 1.4 (1.0; 2.0) 1.4 (1.0; 2.0) 1.7 (1.3; 2.4) –
 IL-1Ra (pg/ml)b 251 (195; 329) 340 (266; 437) 347 (271; 458) 347 (273; 450)
 Adiponectin (µg/ml)b 8.5 (6.2; 12.1) 8.5 (6.2; 12.1) 8.3 (5.9; 11.9) 8.4 (5.8; 12.9)
Heart rate measurements
 Heart rate from ECG (bpm) 64.7 (10.7) 67.3 (11.2) 67.9 (11.6) 66.5 (11.5)
 SDNN (ms) – 34.2 (26.0; 44.8) 33.7(25.4; 44.7) 29.8 (22.0; 40.1)
 RMSSD (ms) – 20.3 (13.6; 29.4) 20.5(13.6; 30.2) 17.5 (11.8; 26.6)
 Low-frequency power  (ms2) – 309 (1657; 569) 284 (157; 524) 222 (113; 439)
 High-frequency power  (ms2) – 128 (615; 251) 115(56; 236) 86 (42; 186)
 LF/HF ratio – 2.6 (1.5; 4.1) 2.6 (1.5; 4.0) 2.6 (1.6; 4.1)
 Total power  (ms2) – 1048 (601;1784) 1004 (568; 1749) 779 (423; 1411)
Page 5 of 9Hansen et al. Cardiovasc Diabetol  (2017) 16:153 
Ta
b
le
 2
 E
ff
ec
ts
 (w
it
h
 9
5%
 C
I)
 o
f a
 d
o
u
b
lin
g
 in
 th
e 
in
fl
am
m
at
o
ry
 m
ar
ke
r 
at
 b
as
el
in
e 
o
n
 5
-y
ea
r 
ch
an
g
es
 in
 h
ea
rt
 ra
te
 a
n
d
 H
R
V
 in
d
ic
es
bp
m
 b
ea
ts
 p
er
 m
in
ut
e,
 d
iff
. d
iff
er
en
ce
, N
 n
um
b
er
 o
f p
er
so
n-
ex
am
in
at
io
ns
 u
se
d 
in
 th
e 
p
ar
tic
ul
ar
 a
na
ly
si
s
p
: p
 v
al
ue
 fo
r t
he
 te
st
 o
f t
he
 e
ff
ec
t b
ei
ng
 e
qu
al
 to
 z
er
o
M
od
el
 1
: A
dj
us
te
d 
fo
r a
ge
, s
ex
, e
th
ni
ci
ty
, s
tu
dy
 p
ha
se
 a
nd
 d
ia
b
et
es
. F
or
 H
RV
 in
di
ce
s,
 fu
rt
he
r a
dj
us
tm
en
t f
or
 h
ea
rt
 ra
te
 o
b
ta
in
ed
 a
s 
p
ar
t o
f t
he
 H
RV
 a
na
ly
se
s
M
od
el
 2
: F
ur
th
er
 a
dj
us
tm
en
t f
or
 B
M
I a
nd
 p
hy
si
ca
l a
ct
iv
it
y
M
od
el
 3
: F
ur
th
er
 a
dj
us
tm
en
t f
or
 s
m
ok
in
g,
 s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e,
 to
ta
l c
ho
le
st
er
ol
, t
rig
ly
ce
rid
es
, t
ric
yc
lic
 a
nt
id
ep
re
ss
an
ts
, d
iu
re
tic
s 
an
d 
b
et
a 
b
lo
ck
er
s
O
ut
co
m
e
M
od
el
h
sC
RP
IL
‑6
IL
‑1
R
a
n
Es
ti
m
at
e
p
n
Es
ti
m
at
e
p
n
Es
ti
m
at
e
p
H
ea
rt
 ra
te
 (b
pm
)
1
13
,2
51
0.
2 
(0
.1
; 0
.3
)
<
 0
.0
01
12
,9
71
0.
1 
(0
.0
; 0
.3
)
0.
10
0
72
41
0.
7 
(0
.4
; 1
.0
)
<
 0
.0
01
2
13
,2
51
0.
1 
(0
.0
; 0
.2
)
0.
05
2
12
,9
71
0.
0 
(−
 0
.2
; 0
.2
)
0.
91
0
72
41
0.
6 
(0
.3
; 1
.0
)
<
 0
.0
01
3
13
,2
51
0.
1 
(0
.0
; 0
.2
)
0.
10
8
12
,9
71
0.
0 
(−
 0
.2
; 0
.1
)
0.
69
6
72
41
0.
6 
(0
.2
; 0
.9
)
0.
00
2
SD
N
N
 (%
 d
iff
)
1
42
58
0.
1 
(−
 0
.7
; 0
.9
)
0.
79
6
42
86
− 
0.
3 
(−
 1
.8
; 1
.3
)
0.
73
1
23
99
− 
3.
2 
(−
 5
.7
; −
 0
.6
)
0.
01
8
2
42
58
0.
3 
(−
 0
.6
; 1
.2
)
0.
50
2
42
86
− 
0.
1 
(−
 1
.6
; 1
.6
)
0.
94
9
23
99
− 
2.
3 
(−
 5
.0
; 0
.6
)
0.
12
0
3
42
58
0.
5 
(−
 0
.4
; 1
.4
)
0.
26
7
42
86
0.
3 
(−
 1
.3
; 1
.9
)
0.
75
0
23
99
− 
1.
8 
(−
 4
.6
; 1
.1
)
0.
22
5
RM
SS
D
 (%
 d
iff
)
1
42
58
0.
5 
(−
 0
.6
; 1
.7
)
0.
37
6
42
86
0.
7 
(−
 1
.5
; 2
.8
)
0.
54
6
23
99
− 
2.
0 
(−
 5
.6
; 1
.7
)
0.
27
7
2
42
58
0.
6 
(−
 0
.7
; 1
.9
)
0.
36
0
42
86
0.
8 
(−
 1
.5
; 3
.0
)
0.
51
3
23
99
− 
1.
1 
(−
 4
.9
; 2
.9
)
0.
58
0
3
42
58
0.
6 
(−
 0
.7
; 1
.9
)
0.
35
4
42
86
0.
7 
(−
 1
.5
; 3
.0
)
0.
52
9
23
99
− 
0.
9 
(−
 4
.9
; 3
.1
)
0.
64
4
Lo
w
 fr
eq
ue
nc
y 
po
w
er
 (%
 d
iff
)
1
42
58
− 
0.
9 
(−
 2
.7
; 0
.9
)
0.
34
2
42
86
− 
1.
8 
(−
 5
.1
; 1
.6
)
0.
29
9
23
99
− 
7.
1 
(−
 1
2.
5;
 −
 1
.4
)
0.
01
6
2
42
58
− 
0.
1 
(−
 2
.1
; 1
.9
)
0.
93
0
42
86
− 
0.
7 
(−
 4
.2
; 2
.9
)
0.
69
4
23
99
− 
3.
9 
(−
 9
.8
; 2
.5
)
0.
22
7
3
42
58
0.
5 
(−
 1
.5
; 2
.5
)
0.
64
5
42
86
0.
1 
(−
 3
.4
; 3
.8
)
0.
93
7
23
99
− 
2.
7 
(−
 8
.8
; 3
.9
)
0.
42
0
H
ig
h 
fre
qu
en
cy
 p
ow
er
 (%
 d
iff
)
1
42
58
0.
6 
(−
 1
.5
; 2
.7
)
0.
58
8
42
86
1.
3 
(−
 2
.5
; 5
.2
)
0.
51
0
23
99
− 
5.
2 
(−
 1
1.
3;
 1
.3
)
0.
11
4
2
42
58
1.
1 
(−
 1
.2
; 3
.4
)
0.
34
7
42
86
2.
0 
(−
 2
.0
; 6
.1
)
0.
33
4
23
99
− 
2.
8 
(−
 9
.5
; 4
.3
)
0.
43
0
3
42
58
1.
2 
(−
 1
.1
; 3
.5
)
0.
29
9
42
86
2.
1 
(−
 1
.9
; 6
.3
)
0.
31
2
23
99
− 
2.
3 
(−
 9
.1
; 5
.0
)
0.
52
4
LF
/H
F 
ra
tio
 (%
 d
iff
)
1
42
58
− 
1.
4 
(−
 2
.7
; −
 0
.2
)
0.
02
7
42
86
− 
3.
0 
(−
 5
.3
; −
 0
.6
)
0.
01
3
23
99
− 
1.
7 
(−
 5
.8
; 2
.6
)
0.
43
3
2
42
58
− 
1.
2 
(−
 2
.6
; 0
.2
)
0.
09
9
42
86
− 
2.
6 
(−
 5
.0
; −
 0
.1
)
0.
03
9
23
99
− 
1.
0 
(−
 5
.4
; 3
.7
)
0.
68
4
3
42
58
− 
0.
7 
(−
 2
.1
; 0
.7
)
0.
31
4
42
86
− 
1.
8 
(−
 4
.3
; 0
.7
)
0.
15
2
23
99
− 
0.
3 
(−
 4
.8
; 4
.5
)
0.
91
3
To
ta
l p
ow
er
 (%
 d
iff
)
1
42
58
0.
0 
(−
 1
.6
; 1
.6
)
0.
97
3
42
86
− 
0.
7 
(−
 3
.7
; 2
.3
)
0.
63
0
23
99
− 
6.
4 
(−
 1
1.
3;
 −
 1
.3
)
0.
01
5
2
42
58
0.
5 
(−
 1
.3
; 2
.3
)
0.
59
6
42
86
− 
0.
1 
(−
 3
.3
; 3
.1
)
0.
93
9
23
99
− 
4.
2 
(−
 9
.5
; 1
.4
)
0.
14
2
3
42
58
1.
0 
(−
 0
.8
; 2
.8
)
0.
28
2
42
86
0.
7 
(−
 2
.5
; 3
.9
)
0.
69
0
23
99
− 
3.
2 
(−
 8
.7
; 2
.6
)
0.
27
4
Page 6 of 9Hansen et al. Cardiovasc Diabetol  (2017) 16:153 
factors that may involve the activation of the NLR family 
pyrin domain containing 3 (NLRP3) inflammasome and 
increased IL-1β activity [21, 22]. Higher IL-1Ra could 
thus be interpreted as result of an endogenous but even-
tually insufficient counter-regulation.
For the three biomarkers of subclinical inflammation 
selected in this study, we found five significant associa-
tions with changes in various HRV indices (LF power, LF/
HF ratio and total power) out of 18 associations tested. 
Therefore, our study provides some evidence that sub-
clinical inflammation may precede both impaired sympa-
thetic and vagal activity, but at the same time indicates 
that BMI represents a major confounder in this con-
text. Overall, effect sizes were small and no clear pat-
tern of associations emerged, so that we did not find a 
pronounced impact of baseline levels of these biomark-
ers on impairments in HRV in our population-based 
study population. Therefore, our results differ from asso-
ciations between inflammation-related biomarkers and 
cardiac autonomic dysfunction in cross-sectional stud-
ies [7]. Moreover, we could not confirm the association 
between CRP levels and increases in HF power from a 
small prospective study [18]. Although direct effects of 
immune activation e.g. induced by lipopolysaccharide 
on HR and HRV have been demonstrated, it is important 
to emphasise that these studies involve acute elevations 
of proinflammatory cytokines that exceed circulating 
levels in the general population by one to two orders of 
magnitude [23]. Collectively, these findings raise the 
question whether associations between biomarkers of 
Table 3 Effects (with 95% CI) of a doubling in adiponectin at baseline on 5-year changes in heart rate and HRV indices 
by diabetes status
For heart rate 400 out of 7241 records were for participants with diabetes. For the HRV indices, 189 out of 2399 records were for participants with diabetes
bpm beats per minute, diff. difference, n number of person-examinations used in the particular analysis
p: p-value for the test of the effect being equal to zero
pinteraction: p-value for interaction with diabetes status
Model 1: Adjusted for age, sex, ethnicity, study phase and diabetes. For HRV indices, further adjustment for heart rate obtained as part of the HRV analyses
Model 2: Further adjustment for BMI and physical activity
Model 3: Further adjustment for smoking, systolic blood pressure, total cholesterol, triglycerides, tricyclic antidepressants, diuretics and beta blockers
Model No diabetes Diabetes pinteraction
n Estimate p n Estimate p
Heart rate (bpm) 1 6841 − 0.3 (− 0.6; 0.0) 0.029 400 − 1.5 (− 2.5; − 0.5) 0.003 0.021
2 6841 − 0.2 (− 0.5; 0.1) 0.119 400 − 1.4 (− 2.4; − 0.4) 0.005 0.022
3 6841 − 0.2 (− 0.5; 0.2) 0.313 400 − 1.3 (− 2.3; − 0.3) 0.014 0.035
SDNN (% diff.) 1 2210 1.3 (− 1.1; 3.7) 0.287 189 10.1 (2.5; 18.2) 0.009 0.027
2 2210 0.7 (− 1.7; 3.1) 0.591 189 9.3 (1.8; 17.4) 0.015 0.028
3 2210 0.0 (− 2.4; 2.5) 0.999 189 8.2 (0.7; 16.3) 0.032 0.036
RMSSD (% diff.) 1 2210 0.3 (− 2.9; 3.5) 0.877 189 13.3 (2.7; 25.0) 0.013 0.018
2 2210 − 0.3 (− 3.6; 3.0) 0.844 189 12.5 (2.0; 24.1) 0.019 0.018
3 2210 − 0.7 (− 4.0; 2.7) 0.680 189 11.8 (1.2; 23.4) 0.027 0.022
Low frequency power (% diff.) 1 2210 3.2 (− 2.1; 8.7) 0.245 189 27.5 (8.7; 49.5) 0.003 0.011
2 2210 1.2 (− 4.1; 6.8) 0.660 189 24.9 (6.5; 46.5) 0.006 0.012
3 2210 − 0.3 (− 5.7; 5.4) 0.916 189 22.5 (4.3; 43.9) 0.013 0.014
All participants
 High frequency power (% diff.) 1 2399 1.7 (− 3.8; 7.6) 0.552 0.267
2 2399 0.1 (− 5.4; 6.1) 0.960 0.303
3 2399 − 1.2 (− 6.9; 4.9) 0.696 0.119
 LF/HF ratio (% diff.) 1 2399 3.2 (− 0.5; 7.0) 0.090 0.319
2 2399 2.9 (− 0.8; 6.8) 0.130 0.314
3 2399 2.7 (− 1.2; 6.8) 0.171 0.342
 Total power (% diff.) 1 2399 4.1 (− 0.5; 9.0) 0.081 0.065
2 2399 2.6 (− 2.0; 7.5) 0.274 0.067
3 2399 1.1 (− 3.7; 6.1) 0.662 0.086
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inflammation and HRV in cross-sectional studies are 
mainly caused by effects of the autonomic nervous sys-
tem on inflammatory pathways [8]. Another small pro-
spective study indeed showed an inverse association 
between HF–HRV and CRP 4  years later [17]. It is also 
possible that subclinical inflammation is so closely linked 
to the autonomic regulation that changes in inflamma-
tion are associated with more immediate changes in 
HRV. This would explain that no temporal association to 
future HRV was seen when adjusting for baseline HRV in 
the present study.
Adiponectin, HR and HRV
The present study demonstrates that higher serum lev-
els of total adiponectin were associated with beneficial 
changes in HR and several measures of HRV 5  years 
after blood sampling in patients with diabetes. The asso-
ciations were present for three of the six HRV indices, 
SDNN, RMSSD and LF power. RMSSD is a marker of 
parasympathetic autonomic tone whereas SDNN and LF 
power are mainly sympathetic measures. This suggests 
that in diabetes patients adiponectin could have neu-
roprotective effects on both branches of the autonomic 
nervous system. There were no significant associations 
between adiponectin and changes in HR or HRV in non-
diabetic individuals indicating that adiponectin may not 
be associated with autonomic regulation in healthy peo-
ple. Reduced HRV is not only strongly associated with 
diabetes in the general population, but already found in 
youth with type 2 diabetes and in adults with prediabetes 
or insulin resistance [24–27]. However, further research 
is necessary to elucidate to what extent determinants of 
reduced HRV and CAN such as adiponectin and other 
biomarkers may depend on age and on the degree of glu-
cose intolerance and hyperglycaemia.
We are not aware of previous prospective studies that 
assessed the potential link between adiponectin levels 
and future changes in HR or HRV. Three cross-sectional 
studies reported that higher adiponectin levels were 
associated with a reduced LF/HF ratio [28], reduced 
very-low-frequency (VLF) power [11] and higher odds 
of CAN [10] in individuals with type 2 diabetes, whereas 
a study based on an occupational sample (prevalence of 
diabetes 2.3%) observed no associations between adi-
ponectin and HRV indices [29]. Thus, the direction of 
associations between adiponectin and HRV or CAN dif-
fers between these aforementioned cross-sectional stud-
ies and our prospective study. Associations between 
higher adiponectin levels and higher cardiovascular 
risk have been reported before in individuals with type 
2 diabetes [16] and may be explained as counterregula-
tory phenomenon as discussed above for IL-1Ra [30] The 
second explanation is of interest because adiponectin 
is upregulated by natriuretic peptides which are direct 
markers of coronary heart disease and could mediate 
such associations [31].
Our findings of favourable associations between base-
line adiponectin levels and changes in both HRV and 
indices of HRV is in line with the inverse association 
between higher adiponectin levels and lower incidence of 
distal sensorimotor polyneuropathy in an older popula-
tion-based cohort with more than half of the participants 
having prediabetes or type 2 diabetes [32]. However, the 
latter association was mediated by obesity and other 
confounders, whereas the association with measures of 
early CAN in the present study was robust to extensive 
adjustment.
Strengths and limitations
Strengths of this study are the large sample size, the com-
prehensive measurements of outcomes and exposures 
assessed simultaneously, the extensive adjustment for 
confounders, the stratification by diabetes status and the 
exclusion of individuals with elevated hsCRP to reduce 
the impact of acute inflammatory states. Importantly, 
the prospective design allowed us to assess the tempo-
ral association between inflammation and HRV changes, 
whereas associations in cross-sectional studies may be 
attributable to reverse causality, i.e. impact of HR and 
HRV on biomarkers of inflammation. Limitations include 
the observational design that precludes causal inferences 
and the selection of four pro- and anti-inflammatory bio-
markers whereas others (e.g. IL-18) also merit further 
research. Furthermore, the study population was pre-
dominantly of European descent, so that data cannot be 
generalised to other ethnic groups. Also, the cohort is 
based on people employed as civil servants at the study 
start excluding e.g. unemployed people and people 
employed in the private sector. The study may therefore 
not be fully generalizable to the general population.
Conclusions
Taken together, we observed that higher IL-1Ra levels 
preceded larger increases in resting HR. Further analy-
ses of hsCRP, IL-6 and IL-1Ra pointed towards BMI-
dependent inverse associations with indices of HRV. 
Higher adiponectin levels showed associations with 
less pronounced increases in HR and a more favourable 
development of sympathetic and vagal tone in individuals 
with type 2 diabetes. The latter associations were absent 
in non-diabetic individuals, so that further studies are 
required to clarify in which contexts adiponectin may 
have therapeutically interesting properties for the long-
term development of autonomic regulation.
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